Skip to main content
. 2020 Aug 17;5(4):e000774. doi: 10.1136/esmoopen-2020-000774

Figure 2.

Figure 2

(A) Progression-free survival (PFS) rates in all patients of the study. (B) PFS by the line of treatment. (C) Overall survival (OS) rates in all patients of the study. (D) OS by the line of treatment. Two patients who received CDKi in combination with tamoxifen were excluded from the OS and PFS analyses. CDKi, cyclin-dependentkinase inhibitor; NE, not evaluable.